anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study 2 will use a treasure task (employed in C.2.1.1), in which participants select amongst 3 keys to learn which feature of keys unlocks the treasure chest, revealing a trial unique object image (Fig. 8b). On each encoding trial participants view three multi-featural keys and a treasure chest. Each key varies on three dimensions: color (red, blue, yellow), shape of the handle (square, circle, triangle), and number of ridges (one, two, three). On each trial, all 9 dimensions of the keys are represented, but the dimensions represented on each key are randomized across trials. During hypothesis testing runs, participants are instructed to find the feature of a key that opens the treasure chest to reveal a trial-unique image. Critically, there is one target feature of a key that deterministically opens the treasure chest. The target feature of the key randomly changes after participants successfully open the chest 4 consecutive times. This design manipulates goal-oriented exploration by allowing participants to resolve uncertainty until they identify the target feature of the key. Uncertainty resolution is the greatest after the target features switches and incrementally reduces via individuals' active hypothesis testing. During control runs, participants will be instructed to select specific keys, and key selection and outcomes will be yolked to prior hypothesis testing runs. Participants will complete 3 runs of hypothesis testing runs and 3 control runs. Trial number for each run is determined by participant behavior, in that hypothesis testing runs end when participants complete 4 rule switches (\~30 trials). Encoding is incidental in this task. Following encoding, participants will complete an immediate and delayed item memory test. On each trial, participants will view objects from the hypothesis testing and control conditions as well as new foil objects. Memory will be tested for half the stimuli immediately and at a 24-hour delay. These memory measures will be related to uncertainty resolution estimated by reinforcement learning, to determine how prior knowledge during information seeking has subsequent effects on memory.
Results from clinical trials in Papua New Guinea and Cote d'Ivoire have shown that a single dose of three drugs (ivermectin, diethylcarbamazine, and albendazole \[IDA\]) was superior to standard two drug therapy (diethylcarbamazine and albendazole \[DA\]) in clearing W. bancrofti microfilaremia (MF) (King et al. unpublished data).1 Recently, large safety studies that treated more than 23,000 participants across four countries were conducted to determine if IDA was safe for use in mass drug administration (MDA) (DOLF Project, unpublished data). Currently, there is no information about what community indicators of infection look like following shorter IDA programs. It is possible that current WHO guidelines for stopping MDA need to be modified for MDA programs that use IDA. Observing the levels of infection indicators in a community following treatment with IDA will provide important information to the GPELF if IDA is recommended for use in MDA programs. There is an opportunity to study communities that were treated with IDA during the "Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis". Communities in this study were randomly assigned to receive IDA or DA treatment. A large percentage of individuals in these communities participated in the study thereby approximating a mass distribution of the treatments. By surveying these communities 12 months following their initial treatment the investigators will be able to better understand and compare the impact of MDA with IDA or DA on LF infection parameters at the level of communities.
The trial is planned to include 40 subjects with acute LVO stroke who meet the eligibility criteria. In stage 1 of the study, the investigators will monitor beat-to-beat blood pressure and other hemodynamic parameters in 20 patients receiving standard of care therapy. For the second stage, the investigators will enroll an additional 20 patients who will receive blood pressure augmentation therapy using intravenous fluids and phenylephrine or norepinephrine infusion. The investigators will increase baseline systolic blood pressure by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The study will assess how quickly a target blood pressure can be reached in the acute stroke setting, and furthermore the ability to successfully maintain these blood pressure targets throughout the intervention and avoid hypotension during conscious sedation or general anesthesia. The primary research hypothesis of the trial is that treatment failure defined as an inability to achieve and maintain blood pressure targets despite the use of maximum tolerable doses of vasopressors (phenylephrine or norepinephrine) occurs in less than 20% of cases. In addition, the study will evaluate the recruitment feasibility and preliminary safety of blood pressure augmentation.
A polypeptide, a nucleic acid molecule, a T-cell receptor or a T-cell displaying the T-cell receptor for use in the prevention or treatment of mesothelioma in a subject is provided. A polypeptide, a nucleic acid, a T-cell receptor or a T-cell displaying the T-cell receptor for use in the prevention or treatment of an epithelioid cancer in a subject is also provided. The polypeptide comprises a region of at least 12 amino acids of a tumour- associated antigen or a sequence having at least 80% identity to the region. The nucleic acid molecule comprises a nucleotide encoding the polypeptide. The T-cell receptor is specific for the polypeptide. The polypeptide, nucleic acid molecule, T-cell receptor or T- cell is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor.
The safety and effectiveness of triamcinolone acetonide nasal spray has been evaluated in 518 children 6 to 12 years of age, and 176 adolescents 12 to 17 years of age [see Clinical Studies (14)]. The safety and effectiveness of triamcinolone acetonide nasal spray in children below 2 years of age have not been established.

Labeling describing use of triamcinolone acetonide nasal spray in pediatric patients 2 to 5 years of age is approved for Sanofi-Aventis U.S. Inc.’s Nasacort® AQ Nasal Spray. However, due to Sanofi-Aventis U.S. Inc.’s marketing exclusivity rights, a description of that use is not approved for this triamcinolone acetonide nasal spray labeling.

Controlled clinical studies have shown that intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The long-term effects of reduction in growth velocity associated with intranasal corticosteroids, including the impact of final adult height are unknown. The potential for “catch-up” growth following discontinuation of treatment with intranasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving intranasal corticosteroids, including triamcinolone acetonide nasal spray, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks/benefits of treatment alternatives. To minimize the systemic effects of intranasal corticosteroids, including triamcinolone acetonide nasal spray, each patient’s dose should be titrated to the lowest dosage that effectively controls his/her symptoms. 

The potential for triamcinolone acetonide nasal spray to cause growth suppression in susceptible patients and when given at higher than recommended dosages cannot be ruled out.
The present invention relates to a technique of lyophilized preparation of meclofenxate hydrochloride and a preparing method thereof. According to the invention, mannitol with effective dose of medicament is added with injection water and is dissolved. The meclofenxate hydrochloride with effective dose of medicament is added and mixed to uniform. The pH value is adjusted to 3-5. The obtained preparing is adsorbed with 0.01% of active carbon and is filtered. Then free drying is executed for preparing the lyophilized preparation. The meclofenxate hydrochloride in the invention is enveloped by macromolecule material and greatly reduces the hydrolytic reaction of meclofenxate hydrochloride. Therefore the lyophilized preparation of meclofenxate hydrochloride prepared by the invention has enough stability in water and can totally satisfy the requirement of clinical medicine taking. Furthermore the lyophilized preparation of meclofenxate hydrochloride prepared by the invention can be stably and slowly released. The bioavailability of meclofenxate hydrochloride is increased and transparency after re-dissolving is excellent.
The first group will receive a standard health education for self-care practices done by attending two appointments in our clinics with the health education and dietitian in a personal session. The HA1C blood test together with completing a brief questionnaire form measuring the Diabetes Self-Care Activities during the past three months will be done after 3 and, 6 months will be done.
Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
An automated health care facility for the administration of medication to patients is disclosed. The automated health care facility can include a plurality of data entry terminals for entry of information such as prescription information identifying a prescription of medication to be provided to a particular patient. A pharmacy, for receiving prescription information from the data entry terminals prepares and dispenses medication in accordance with the prescription. A patient database can be used to store patient data information, and a pharmaceutical database can be used to store information relating to one or more medications such as those dispensed by the pharmacy. An automated medicated infusion device prepares and administers medications to a patient. Information in one or more databases can be accessed to assist in prescribing medication and preventing medication errors.
BACKGROUND: Conventional anesthesia used to reduce central venous pressure (CVP) during hepatectomy includes fluid restriction and vasodilator drugs, which can lead to a reduction in blood perfusion in vital organs and may counteract the benefits of low blood loss. In this study, we hypothesized that milrinone is feasible and effective in controlling low CVP (LCVP) during laparoscopic hepatectomy (LH). Compared with conventional anesthesia such as nitroglycerin, milrinone is beneficial in terms of intraoperative blood loss, surgical environment, hemodynamic stability, and patients' recovery.
METHODS: In total, 68 patients undergoing LH under LCVP were randomly divided into the milrinone group (n = 34) and the nitroglycerin group (n = 34). Milrinone was infused with a loading dose of 10 µg/kg followed by a maintenance dose of 0.2-0.5 µg/kg/min and nitroglycerin was administered at a rate of 0.2-0.5 µg/kg/min until the liver lesions were removed. The characteristics of patients, surgery, intraoperative vital signs, blood loss, the condition of the surgical field, the dosage of norepinephrine, perioperative laboratory data, and postoperative complications were compared between groups. Blood loss during LH was considered the primary outcome.
RESULTS: Blood loss during hepatectomy and total blood loss were significantly lower in the milrinone group compared with those in the nitroglycerin group (P < 0.05). Both the nitroglycerin group and milrinone group exerted similar CVP (P > 0.05). Nevertheless, the milrinone group had better surgical field grading during liver resection (P < 0.05) and also exhibited higher cardiac index and cardiac output during the surgery (P < 0.05). Significant differences were also found in terms of fluids administered during hepatectomy, urine volume during hepatectomy, total urine volume, and norepinephrine dosage used in the surgery between the two groups. The two groups showed a similar incidence of postoperative complications (P > 0.05).
CONCLUSION: Our findings indicate that the intraoperative infusion of milrinone can help in maintaining an LCVP and hemodynamic stability during LH while reducing intraoperative blood loss and providing a better surgical field compared with nitroglycerin.
TRIAL REGISTRATION: ChiCTR2200056891,first registered on 22/02/2022.
The group was leaded by two psychologists trained on trauma and disaster psychology, and group intervention. Each groups lasted 2.50 hours.
The purpose of the CHART research study is to assess the value of a novel multi-level intervention for low-income patients recently hospitalized with heart failure relative to providing education alone (both strategies are described in detail in the Intervention section below). The investigators refer to their novel intervention strategy as 'Enhanced Training' and their education-only strategy the investigators refer to as 'Enhanced Education'. These two strategies of participant follow-up will be assessed and compared by analyzing patient's all-cause hospital days over a 2.5-year follow-up period (the investigators note that, for patients with heart failure, the average number of such all-cause hospital days over a 2.5-year period has tripled over the past 25 years). The Enhanced Training strategy aims to improve patient receipt of evidence-based therapy by: 1) activating patients using a culturally sensitive approach that might better resonate with the investigators predominantly urban, African-American and Hispanic, target population; 2) providing timely and useful information to the primary care provider; and 3) promoting effective communication between patients and their primary care provider. The Enhanced Education strategy is less intrusive and aims to provide patients and primary care providers with appropriate educational materials via mail. The primary aims of this research study are to determine if Enhanced Training and/or Enhanced Education will improve: patient adherence to drug therapy and salt restriction, health care provider adherence to evidence-based guidelines, and patient functional capacity and quality of life. Secondary aims will include assessing impact of the interventions on CRP and BNP, which are two key biomarkers of heart failure progression.
The present invention relates to compositions and treatment methods which include or employ a novel macrophage-derived stable cytolytic antitumor factor, termed Cytolytic Factor (CF). Production/release of CF by the macrophage required transcription, translation, glycosylation, and an intact secretory apparatus, as evident from its inhibition by treatment with actinomycin D, cycloheximide, tunicamycin, and monensin, respectively, prior to and during triggering with LPS. CF obtained by culture of BCG-activated macrophages appeared rapidly in the supernatant after triggering. Using the actinomycin-D treated L-929 or EMT-6 targets in a microassay, CF secreted by macrophages cultured in low molecular weight serum components was detected as a -150 kD component on Sephacryl S-200 and was stable at 4°; when the macrophages were instead cultured in lactalbumin hydrolysate, the CF appeared to be unstable at this temperature. CF demonstrated a spectrum of cytotoxic activity against a number of tumor and normal targets in vitro. CF was moderately sensitive to treatment with TLCK and TAME. A rabbit heteroantiserum raised against highly purified necrosin, a product of the murine macrophage cell line J774.1, was extremely effective in neutralizing the biological activity of CF.
Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 \[fasted and fed dosing conditions\]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety/tolerability, PK, and PD data from previous cohorts.
ABSTRACT OF THE DISCLOSURE:         The invention comprises compounds and methods of preparation of a large area of basic derivatives of linearly condensed tricyclic systems formed by two external benzene nuclei and a central seven-membered ring with two chalcogen atoms as hetero atoms   When both of the chalocogens are atoms of oxygen, we are dealing with derivatives of 11H-dibenzo(b,e)-1,4-dioxepin; when both of the chalcogens are sulfur atoms, we are dealing with derivatives of 11H-dibenzo (b,e)-1,4-dithiepin and in the case of the both possible combinations of atoms of oxygen and sulfur we are dealing with derivatives of 6H-dibenz(b,e)-1,4-oxathiepin and 11H-dibenz(b,f)-1,4-oxathiepin. Compounds according to the invention contain in molecules various types of aminoalkyl groups connected to the single carbon atom of the central ring which may be considered (dimethylaminomethyl, 2-dimethylaminoethyl, 2-methylaminoethyl, 3-dimethylaminopropyl, 3-methylaminopropyl, 3-piperidinopropyl, 1-methyl-3-piperidyl-methyl, 1-methyl 4-piperidyl.  Some of the compounds according to the invention are substituted in the benzene rings with atoms of halogens, with methoxyl, trifluoromethyl, trifluoro-methylthio group.  The invention includes not only the bases but also their salts with pharmaceutically acceptable acids. The invention includes also several methods for the prepara-tion of the compounds defined consisting in (a) construction of the whole molecules by cyclization of the diaryl ether or diaryl sulfide derivatives with a preformed side chain,  (b) introduction of the side chains into the first synthesized tricyclic systems, (c) modification of the side chains in the amino group fragment, (d) selective oxidations to N-oxides, sulfoxides or sulfones.  The compounds of the invention have mild or very intensive psychotropic activity and in agreement with their structures they are neuroleptics, tranquillizers and antidepressants.
BACKGROUND: Persistent cognitive impairment is a serious consequence of the post-COVID condition. However, there have been no established effective treatments for this pathophysiology supported by sufficient evidence.
CASE PRESENTATION: A 32-year-old woman became aware of difficulty in word recalling, reading, and writing as well as difficulty in completing various household multitasks 3 weeks after the COVID-19 infection. Although blood tests, magnetic resonance imaging, electroencephalography, and Kohs block design test were all within normal limits, completion time by trail making test (TMT) A or B was markedly delayed. Finally, she was referred to our hospital 3 months after the infection. At baseline, the THINC integrated tool (THINC-it), a digital battery consisting of the five-item version of the perceived deficit questionnaire (PDQ-5), choice reaction time (CRT), 1-back test, digit symbol substitution test (DSST), and TMT-B, revealed poor capability in attention, working memory, and executive function. Also, near-infrared spectroscopy (NIRS) demonstrated no activation in frontal or temporal regions during verbal fluency task. Extended-release guanfacine (GXR) 2 mg/day was initiated and a month later was elevated up to 4 mg/day as a maintenance dose. The PDQ-5, CRT, 1-back test, DSST, and TMT-B were dramatically improved 1 month after GXR treatment. NIRS finding was also normalized after 2 months of treatment. These effects were successfully maintained throughout the 6-month follow-up period.
CONCLUSION: GXR may be helpful in improving subjective/objective cognitive functioning and frontotemporal brain activity in long-COVID patients manifesting apparent cognitive impairment.
OBJECTIVES: Acute type A aortic dissection (ATAAD) remains a highly life-threatening condition. This study investigates factors associated with fatal ATAAD prior to surgical treatment.
METHODS: We reviewed autopsy reports of ATAAD decedents who died before surgical intervention and underwent postmortem examination at our clinic from 1994 to 2022.
RESULTS: Among 94 eligible cases, 50 (53.2%) decedents had DeBakey type I dissection, and 44 (46.8%) had DeBakey type II dissection. Most were males, 63 (67%), and 72 (77%) had a history of hypertension. The median age was 70.5 years, and the type II group was a decade older than the type I group (P < 0.001). Decedents in the type II group predominantly died during the first hour after symptoms onset 16 (52%), while in the type I group, fatalities occurred between 1 h and 1 day, 27 (66%). The most common site of the intimal tear was the midportion of the ascending aorta, 45 (48%). The median ascending aorta size was 5 cm for the entire cohort, 5.2 cm for type I and 4.6 cm for type II (P < 0.045).
CONCLUSIONS: In this autopsy study of fatal acute aortic dissection, the median aortic size was below the current guideline threshold for elective repair. Type II acute aortic dissections were found more frequently than expected and were characterized by older age, advanced aortic atherosclerosis, smaller aortic size, a shorter interval from symptom onset to death and a higher frequency of syncope compared to type I dissection.
Provided are methods for screening a subject for cancer. The methods involve obtaining a blood sample from the subject and determining a level of Bridging Integrator 1 (BIN1) isoforms comprising exon 12a in the sample. Optionally, the method involves determining a level of 12a+/13− BIN isoform (comprising exon 12a but lacking exon 13) in the sample. An elevated level of 12a+ (e.g., 12a+/13−) BIN1 isoforms in the blood sample indicates the subject has cancer. Also provided are methods for determining efficacy of a cancer therapy in a subject and methods of treating cancer. Isolated antibodies that selectively bind human 12a+ BIN1 are also provided as well as kits for determining 12a+/13− BIN1 isoforms.
Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir, amantadine, rimantadine, and combinations thereof. The polymer is preferably a water-soluble, biocompatible polymer. Suitable polymers include, but are not limited to, poly(isobutylene-α/Mnaleic anhydride) (PIBMA)5 poly(aspartic acid), poly(l-glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof. In another embodiment, the compositions contain a physical mixture of polymer containing one antiviral agent and polymer containing a second antiviral agent. The compositions can be formulated for enteral or parenteral adminstration. Suitable oral/intranasal dosage forms include, but are not limited to, tablets, capsules, solutions, suspensions, emulsions, syrups, and lozenges. Suitable dosage forms for parenteral administration include, but are not limited to, solutions, suspensions, and emulsions. The compositions described herein are effective at treating a variety of infections, including viral infections such as influenza, while inhibiting or preventing the development of microbial resistance.